RIGL Rigel Pharmaceuticals, Inc.
$50.55▲ +1.28%
Healthcare
Other
Volume 133.1K
Avg Volume (10D) 195.2K
Key Metrics & Fundamentals
Market Cap
$944.27M
P/E Ratio
3.0
Div Yield
0.00%
52W Range
24.95 - 52.24
% vs 50 MA
6.78%
% vs 200 MA
36.75%
RSI-14
62.3
MACD Histogram
+0.2000
Beta (1Y vs SPY)
0.84
Free Cash Flow
-$39.69M
Gross Rev
$78.70M
Gross Profit
$70.18M
EBITDA
$25.21M
COGS
$8.53M
Operating Exp
$46.60M
Operating Income
$23.58M
EBIT
$23.58M
Pretax Income
$23.59M
Net Income
$17.29M
EPS (Diluted)
0.88
Price & Volume History
Loading chart…
Recent News
Rigel Pharmaceuticals Shares Rose Even As Profit Fell
Simply Wall St. · Oct 23, 2026 5:12 PM ET
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
PR Newswire · Oct 19, 2026 8:05 AM ET
Reasons Why Investors Should Consider Betting on Arvinas Stock
Zacks · Oct 13, 2026 10:27 AM ET
Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
GlobeNewswire · Oct 6, 2026 7:30 AM ET
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PR Newswire · Oct 2, 2026 8:05 AM ET
Myelodysplastic Syndrome Market Set for Strong Growth During the Forecast Period (2026-2036) as Targeted Therapies and Novel Treatment Approaches Reshape the Landscape | DelveInsight
PR Newswire · Sep 15, 2026 10:31 AM ET
Rigel to Participate in Upcoming September Investor Conferences
PR Newswire · Sep 2, 2026 8:05 AM ET
Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope
Simply Wall St. · Aug 16, 2026 1:08 AM ET
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
BioPharma Dive · Aug 14, 2026 5:28 AM ET
Rigel Says Breast Cancer Drug Veppanu Now Available in US, Puerto Rico
MT Newswires · Aug 13, 2026 9:42 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See RIGL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.